Inspire Medical Systems, Inc. (INSP) company profile
Close on Nov 17, 2026Market cap $1.72BP/E 12.9Yield –
About Inspire Medical Systems
Surgical & Medical Instruments & Apparatus, SIC 3841
The company develops and commercializes minimally invasive neurostimulation technologies for patients with obstructive sleep apnea. Its main product is the Inspire system, including the Inspire IV and Inspire V models, which monitors breathing and delivers mild hypoglossal nerve stimulation to keep airways open during sleep. The system includes an implantable neurostimulator, leads, a remote control, and the digital SleepSync management platform. The company sells its medical devices to hospitals and ambulatory surgery centers, while collaborating with ear, nose, and throat doctors, sleep centers, and patients.
As of December 31, 2025, the firm maintains 295 sales territories across the United States and 21 international territories. It markets directly to healthcare providers in the United States and select European countries, and uses distributors in Asian markets including Japan, Singapore, Hong Kong, and Thailand. More than 125,000 patients have received the therapy across the United States, Europe, and Asia. The provided text does not state the company's headquarters.
Summary of the business section of Inspire Medical Systems's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Inspire Medical Systems, Inc.
- Founded
- 2007
- Headquarters
- Golden Valley, MN
- Address
- 5500 Wayzata Blvd, Suite 1600 55416
- Phone
- (763) 957-5037
- Website
- inspiresleep.com
- Employees
- 1,333, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Minneapolis, MN
Stock & identifiers
- Ticker
- INSP
- Exchange
- NYSE
- IPO date
- May 4, 2018
- Shares outstanding
- 29M, Jul 30, 2026
- Public float
- $3.80B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1609550
- CUSIP
- 457730109
- ISIN
- US4577301090
- FIGI
- BBG00209SZJ7
- Share class FIGI
- BBG00209SZK5
- LEI
- 549300XQQCQ7HCJKTW25
- EIN
- 26-1377674
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Timothy P. Herbert | CEO and President, Director | 105,349 |
| Jason P. Kelly | See Remarks | 25,335 |
| Melissa Mann | Chief People Officer | 22,957 |
| John Rondoni | See Remarks | 27,165 |
| Bryan K. Phillips | See Remarks | 38,513 |
| Carlton Weatherby | See Remarks | 41,679 |
| Matthew J. Osberg | Chief Financial Officer | 19,794 |
| Richard Buchholz | Interim CFO | 45,463 |
| Randy Ban | See Remarks | 9,303 |
| Michael H. Carrel | Director | 5,834 |
| Shelley G. Broader | Director | 9,138 |
| Georgia Melenikiotou | Director | 8,584 |
| Gary Lee Ellis | Director | 11,850 |
| Casey M. Tansey | Director | 27,132 |
| Shawn mcCormick | Director | 30,712 |
| Cynthia Burks | Director | 6,213 |
| Dana G. Mead Jr. | Director | 26,213 |
| Myriam Curet | Director | 6,927 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $7.71M | -$869.71K | $2.74M | $49 | $78 |
| FY2024 | $8.11M | $2.50M | $2.85M | $99 | $78 |
| FY2023 | $7.49M | $876.35K | $2.18M | $108 | $74 |
| FY2022 | $5.68M | $8.35M | $2.14M | $134 | $79 |
| FY2021 | $1.27M | $10.64M | $1.13M | $122 | $103 |
| FY2020 | $4.87M | $21.66M | $2.46M | $253 | $133 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Timothy P. Herbert President and Chief Executive Officer | $750.57K | $6.00M | $961.56K | – | $7.71M | -5% |
| Randall A. Ban Chief Commercial Officer (6) | $490.79K | $1.90M | $328.05K | $10.50K | $2.73M | -4% |
| Richard J. Buchholz Chief Financial Officer (6) | $477.99K | $1.90M | $319.49K | $10.26K | $2.71M | -4% |
| Bryan K. Phillips SVP, General Counsel, CCO and Corporate Secretary | $475.18K | $1.90M | $317.61K | $9.74K | $2.70M | -5% |
| Carlton W. Weatherby Chief Strategy Officer (6) | $506.25K | $1.90M | $428.89K | – | $2.84M | -2% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- May 4, 2018
- Offer price
- $16.00
- Securities offered
- 6,750,000
- Gross proceeds
- $108.00M
- Exchange
- NYSE
- First trading day
- May 3, 2018
- First-day close
- $24.98+56.1%
- Lock-up ends (est.)
- Oct 30, 2018
“Per Share Total Public offering price $16.00 $108,000,000 Underwriting discount(1) $1.12 $7,560,000 Proceeds, before expenses, to us $14.88 $100,440,000 (1) We refer you to "Underwriting" beginning on page 166 for additional information regarding underwriting compensation.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 1,333 employees, of which 1,243 are in the U.S., 83 are in Europe and 7 are in Japan.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 4, 2018 | IPO | Initial public offering priced (424B4 prospectus) |
| Apr 24, 2018 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?